Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 31, 2024 1:24pm

90 Views

Post# 36156542

RE:RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

July 31, 2024 - Merck USA (MSD) HPV sales in China have been impacted by an “anti-bribery” and "anti-corruption” drive that China has conducted in China corruption crackdown.

Merck's CEO Rob Davis said on Tuesday that China accounts for between 60% and 70% of Gardasil’s international sales. In China, the vaccine is handled by Merck’s commercial partner, Zhifei Biological Products.

https://www.fiercepharma.com/pharma/merck-mystified-sudden-step-down-gardasil-sales-china

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season